Right2Breathe® and Allergy & Asthma Network to Offer Free Asthma Screenings during NHRA Four-Wide Nationals

Thanks to funding provided by Novartis®, Right2Breathe® and Allergy & Asthma Network will offer free Asthma Screening and spirometry exams to measure lung function during NHRA Four-Wide Nationals in Concord, NC April 28th – 30th at Z-Max Dragway

Flemington, NJ. – Right2Breathe® Inc., a 501 (c)(3) non-profit organization based in Flemington, NJ is proud to announce a partnership with Allergy & Asthma Network to provide free spirometry exams, educational materials and screenings for Asthma during the NHRA Four-Wide Nationals held at Bruton Smith’s Z-Max Dragway in Concord, NC; April 28th – 30th.

The Right2Breathe® Free Asthma Screening program; which is funded by a grant provided by Novartis®, is the non-profit’s first to be held at a NHRA National Event. Right2Breathe® successful debuted their program at the NHRA California Hot Rod Reunion held in October 2016. In Bakersfield the Right2Breathe® team screened hundreds of drag racing fans, drivers and vendors for COPD, or Chronic Obstructive Pulmonary Disease. Right2Breathe® co-founders Joe Morrison and Tim Charlet; second-generation drag racers themselves, are expecting to double those numbers by inviting fans, race team members, and vendors to “Put their Lungs on the Dyno” during the sensory overload that is the NHRA Four-Wide Nationals.

Asthma is a long-term (chronic) lung disease that causes episodes of coughing, wheezing and shortness of breath. Like all chronic illnesses, asthma cannot be cured, but it is very manageable; especially once a patient is correctly diagnosed. Several genetic and environmental factors such as family history, exposure to secondhand smoke, and environmental irritants have all been identified as risk factors for asthma.

One of the first steps in beginning the treatment of Asthma is completing a non-invasive and simple spirometry exam, which will be administered by professional Respiratory Therapists and other medical professionals in the Right2Breathe® Screening area located in the manufactures midway all three days during the event. An estimated 17.7 million adults and 6.3 million children in the United States live with Asthma. Allergy & Asthma Network President and CEO Tonya Winders believes the Right2Breathe® NHRA screening event is an exceptional opportunity to engage with an estimated 50,000 race fans expected to attend the race in Concord.

“We are excited to partner with Right2Breathe® on this asthma screening event and increase awareness of asthma prevalence and treatment,” says Tonya. “The screening is a chance for individuals to be tested for this life-changing medical condition when they might not otherwise have the opportunity. Approximately 10 people per day die from asthma, so it’s important to be diagnosed early and develop a treatment plan with a doctor.”

The Right2Breathe® Project will be set up in the vendor’s midway, located on the professional pit side of Z-Max Dragway. Fans are encouraged to stop by the Right2Breathe® display in the midway to sign up for free daily raffles and prizes, and receive educational materials not only about Asthma and other respiratory disease, but also how allergies can also impact respiratory health. The Right2Breathe® Screening area will be open Friday from noon till 5pm, Saturday from 9:30 am till 4pm and Sunday 9:30 till 3pm.

As always, fans will have the opportunity to interact with their favorite NHRA drivers, as Every Ticket’s a Pit Pass® at the most powerful and sensory-filled motorsports attraction on the planet. Get direct access to the teams, see firsthand as the highly-skilled mechanics service their hot rods between rounds, and get autographs from NHRA drivers for no additional cost.

Tickets can be purchased online or by calling 800-455-FANS (3267). Purchase early and save!

About Allergy & Asthma Network

Allergy & Asthma Network is the leading national nonprofit organization dedicated to ending needless death and suffering due to asthma, allergies and related conditions. Allergy & Asthma Network specializes in sharing family-friendly, medically accurate information through its award-winning publication Allergy & Asthma Today magazine, E-newsletter, http://www.AllergyAsthmaNetwork.org and numerous community outreach programs. Follow Allergy & Asthma Network on Facebook at facebook.com/AllergyAsthmaHQ and Twitter at twitter.com/AllergyAsthmaHQ. Join Allergy & Asthma Network at http://www.AllergyAsthmaNetwork.org/join.

About Right2Breathe®

Right2Breathe® Inc. is a 501 (c)(3)non-profit organization based in New Jersey, created by two passionate Drag Racers who have a personal mission to improve the quality of life for those that live with respiratory difficulty, illness or disease. They are dedicated to educating the automotive and motorsports community about pulmonary or respiratory medical conditions through a cause marketing campaign including but not limited to:

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma
  • Idiopathic Pulmonary Fibrosis
  • Cystic Fibrosis
  • Lung Cancer

The Right2Breathe® Campaign is comprised of two separate but equally important projects, The Right2Breathe® Project is aimed at providing Free COPD Screening, Education and Awareness at motorsports and automotive events across the United States, and a recently launched Youth Tobacco Prevention and Adolescent Asthma education program called “Burnouts4Kids – A Right2Breathe Campaign”. Learn more about Right2Breathe by visiting their website at http://www.Right2Breathe.org.

For Media Inquiries, please contact: Tim Charlet – Chief Marketing Officer – Right2Breathe®

Email: TimC@Right2Breathe.org Phone: 435-669-8561

/ In COPD Screening / By admin / Comments Off on Right2Breathe® and Allergy & Asthma Network to Offer Free Asthma Screenings during NHRA Four-Wide Nationals

Make Your Voice Heard – CMS Reducing Respiratory Therapy Reimbursement in 2017

Respiratory therapy works for ALL respiratory diseases. The research, science and years of studies have confirmed this statement of fact. However, in a period where official diagnosis and cases of Asthma, Allergies, and Chronic Obstructive Pulmonary Disease (COPD) are RISING, the Centers for Medicare and Medicaid Services (CMS) recently announced a reduction in the amounts they will allocate for pulmonary rehabilitation starting in 2017.

Respiratory Therapist and Right2Breathe Director of Education Michele DaSilva speaks with a recently diagnosed COPD patient about some of the benefits of pulmonary rehab at the recently completed Right2Breathe FREE COPD Screening event in Bakersfield, California.

It is not news that too many COPD patients struggle to gain access to the few programs currently available. Due to an already too low reimbursement, along with the restriction on the total amount of pulmonary rehabilitation visits they are permitted during their lifetime, there simply are not enough programs to meet the demand from our community. Many programs struggle to remain in operation because of the low reimbursement from CMS. Moreover, the low rate discourages development of new programs in areas where access is non-existent.

The CMS announced final rules that update payments to hospitals under the Hospital Outpatient Prospective Payment System beginning Jan. 1, 2017 (CY 2017). These rules include payment for Pulmonary Rehabilitation. The problem however is that although it’s assumed that these reductions are designed to save costs; the reality exists that these reductions in reimbursement will restrict patients covered by Medicare and Medicaid to receive quality pulmonary rehabilitation for all respiratory conditions.

COPD patient and double-lung transplant recipient Mel Bryson is living proof that pulmonary rehabilitation works.
COPD patient and double-lung transplant recipient Mel Bryson is living proof that pulmonary rehabilitation works.

Fortunately the payment rates are not final, yet. Those impacted with respiratory illness, disease or afflictions ranging from currently diagnosed patients, to caregivers and friends and family of people who depend on pulmonary rehabilitation have until December 31st, 2016 to do something about this proposed change. The voice of those actually living with diseases is incredibly impactful to government lead programs such as the CMS.

The Right2Breathe Project, in conjunction with the US COPD Coalition are asking all who have benefitted or currently depend on the hard work of pulmonary professionals to take a few moments to submit your support of this industry and displeasure in the CMS’s reduction in reimbursement for the following Ambulatory Payment Classification group to which these codes were to be assigned has also changed.

  • G0237 — Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring)
  • G0238 — Therapeutic procedures to improve respiratory function, other than described by G0237, one on one, face to face, per 15 minutes (includes monitoring)
  • G0239 — Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes monitoring)
  • G0424 — Pulmonary Rehabilitation, including exercise (includes monitoring), one hour, per session, up to two sessions per day

This is an exceptional opportunity for us to make a difference, and help CMS recognize that pulmonary rehabilitation will save money in the short and long term, but more importantly that it provides COPD patients and those living with other respiratory diseases with access to the only scientifically proven, non-pharmacological clinical intervention.

Now, here’s how to submit your comment.

CMSContact1

Submit your comments electronically at by hitting the “comment now” button above. By clicking that button, you’ll be directed to the CMS feedback page. We invite you to express your concern about their decision, and how pulmonary rehabilitation helps you or those you love live a higher quality of life.

Remember – Everybody Has A Right2Breathe – and the Right to effective healthcare.

Right2Breathe™ Project to Offer Free COPD Screenings During NHRA Event at Auto Club Famoso Raceway

With the assistance of Novartis, Sunovion, NDD Medical Technologies, Inc, Pack Health and Drive-DeVilbiss® Healthcare, the Right2Breathe™ Project will offer free COPD Screening and spirometry exams to measure lung function during 25th Edition of the NHRA California Hot Rod Reunion October 21st – 23rd at Auto Club Famoso Raceway in McFarland, Calif.

R2BBlackSticker1Flemington, NJ. – Right2Breathe™ Inc., a non-profit organization based in Flemington, NJ is proud to announce a partnership with several pharmaceutical and healthcare industry partners to provide free spirometry exams and screenings for Chronic Obstructive Pulmonary Disease (COPD) to the estimated 50,000 race fans planning to attend the 25th running of the NHRA California Hot Rod Reunion, this upcoming weekend, October 21st through 23rd contested at Auto Club Famoso Raceway in McFarland, Calif.

The Right2Breathe™ Project was co-founded in July 2014 by Joe Morrison and Tim Charlet; two second-generation Drag Racers who have personal experience as caregivers for family members with pulmonary disease including COPD. The Right2Breathe™ Project is targeted to a passionate fan-base of over 50 million individuals in the United States; who share a common passion for motorsports and automotive industry as the organizational co-founders that due to their vocation or lifestyle choices are at high-risk for developing respiratory medical conditions.

Their onsite COPD Screening is a critical element of Right2Breathe’s mission to help diagnose an estimated 12 million Americans; who according to the Center for Disease Control in Atlanta are currently living with COPD – but have not yet been screened or properly diagnosed. COPD is the third leading cause of death in the United States. According to the American Lung Association, more than 11 million people have been diagnosed with COPD in the United States, but millions more may have the disease without even knowing it. COPD causes serious long-term disability and early death. At this time there is no cure, and the number of people dying from COPD is growing.

“COPD rings home for me and is the core inspiration for Right2Breathe™,” stated Joe Morrison, CEO of Right2Breathe™. “My father was a plumber for several years who raised me in the sport of NHRA Drag Racing. Together we’ve had an active role in New Jersey supporting COPD education, screening and awareness for the past four years. Although he recently passed away due to complications from COPD, my dad’s inspiration strengthens our resolve.”

“Thanks to the support of healthcare industry leaders including NDD Medical Technologies, Inc., Novartis, Sunovion Pharmaceuticals Inc., Pack Health and Drive DeVilbiss® Healthcare; we are able to expand our reach directly to our target demographic at this year’s California Hot Rod Reunion. NDD Medical is not only providing their advanced spirometry equipment and screening supplies, but they will also be onsite to help train existing and future respiratory therapists on how to better utilize their spirometry equipment; as we have students from San Joaquin Valley College-Bakersfield Campus joining us as well. Thanks to their support of the Right2Breathe™ Project we are able to accomplish our mission to educate the extensive motorsports fan base about the dangers of COPD and provide them with tools and resources to reduce their risk potential.”

A leader in lung function testing based in Switzerland and the U.S., NDD Medical Technologies is helping to improve the quality of life for millions of people living with lung disease. Built around the company’s patented Ultrasonic TrueFlow™ technology, NDD’s innovative, easy-to-use products such as EasyOne® and EasyOne Pro® help clinicians diagnose and treat COPD and other chronic lung diseases earlier and with greater precision by providing accurate information at the point of care.

“NDD is committed to improving the quality of life for millions of people worldwide living with COPD,” said Georg Harnoncourt, CEO for NDD Medical Technologies. “We are pleased to partner with Right2Breathe to provide free, onsite screenings with the innovative lung function testing tools that we have developed to increase early detection and accurate diagnosis of COPD and other chronic lung conditions.”

Leading the COPD Screening efforts is Michele DaSilva, BA, RRT-NPS, who serves as Right2Breathe’s Director of Education. DaSilva will be supported by a team multiple medical professionals including licensed Respiratory Therapists who are volunteering their time to support this free COPD Screening event.

The Right2Breathe™ Project will be set up in the vendor’s midway at Auto Club Famoso Raceway and will offer their free COPD Screenings and spirometry testing Friday through Sunday, from 9:00 am till 4:00 pm. Fans are encouraged to stop by the Right2Breathe™ display in the midway to sign up for free daily raffles and prizes, including collectable’s from this special Silver anniversary of the annual CHRR.

Admission to the event at Auto Club Famoso Raceway is $25.00 where automotive race fans will be entertained by over 500 of the best NHRA Heritage Series drag racers on the planet; including Right2Breathe’s CEO Joe Morrison, who will be driving his popular 1948 Fiat Altered in Nostalgia Eliminator One and Ted Brine’s legendary 134 Fuel Coupe in the AA/Fuel Altered division.

To learn more about the Right2Breathe™ Project, please visit their website at https://www.right2breathe.org. You can also follow them via social media locations on Facebook at http://www.facebook.com/right2breathe and on Twitter @Right_2_Breathe. To learn more about NDD Medical Technologies, Inc., please visit http://www.nddmed.com or follow on Twitter @nddMedical.

For Media Inquiries, please contact: Tim Charlet – Chief Marketing Officer – Right2Breathe™

Email: TimC@Right2Breathe.org Phone: 435-669-8561

Joe Morrison Set to Pull Driving Double-Duty at The California Hot Rod Reunion

Right2Breathe™ Project co-founder and CEO to pilot Iconic 134 Fuel Coupe and Right2Breathe™ 48 Fiat Altered in Nostalgia Eliminator 1 at Auto Club Famoso Raceway.

Flemington, NJ. – Ted Brine’s Iconic 134 Fuel Coupe is back. The 1934 five window Ford nitro-burning coupe has been rebuilt after a horrible accident at last year’s California Hot Rod Reunion and driver Joe Morrison is anxious to get back in the saddle in the Fuel Altered category during the Silver Anniversary edition of the NHRA California Hot Rod Reunion. Morrison will also complete in the ultra-competitive NE1 category with his Novartis® and Sunovion® backed 1948 Fiat Topolino Right2Breathe™ Nostalgia Altered.

Morrison, from Flemington, NJ has fond memories of legendary Auto Club Famoso Raceway and some he’d like to forget. In 2014, he successfully upgraded his NHRA competition license to the Top Alcohol Dragster category driving Jerry Darien’s A/Fuel Dragster, recording a career best 5.37 elapsed time at a tick just under 270 mph. However, at last year’s CHRR, Morrison was piloting Ted Brine’s 134 Fuel Coupe when the car made a hard turn towards the center line, and snapped back to impact the guard rail head on. The car flipped over on its side and slid down the all-concrete quarter mile drag strip until Morrison deployed the parachutes, flopping the damaged 34 Fuel Coupe back onto its wheels.

Although Morrison was uninjured in the incident, it left the veteran driver itching to return to the 2016 California Hot Rod Reunion for some redemption. Thanks to the financial backing of Pharmaceutical companies Novartis® and Sunovoin®, along with medical industry leaders NDD Medical, Pack Health and Drive-Devilbiss Healthcare, Morrison has the opportunity to double his pleasure and double his fun.

“I remember every detail about that run in Ted’s 134 Fuel Coupe and those are memories I’m bound and determined to never relive,” stated Morrison, who serves as the Chief Executive Officer and co-founder of Right2Breathe™, a non-profit organization that provides Education, Awareness and Free Screenings for respiratory medical diseases including Chronic Obstructive Pulmonary Disease (COPD), Asthma and Allergies and other respiratory illnesses. “Big Daddy Don Garlits said it best, ‘It’s not a question of whether you will have an accident in drag racing; but when it will occur’. Hopefully I’ve gotten mine under my belt and we can put on a great show for the estimated 50,000 California Hot Rod Reunion fans that will be on-site for the 25th anniversary of this outstanding event.”

While his anticipation to return to Auto Club Famoso Raceway was primarily motivated by competing at the event, Morrison also received notification recently that his Right2Breate Project collected a much needed financial boost from Novartis®, Sunovion®, NDD Medical, Pack Health, and Drive-Devilbiss Healthcare to host their first NHRA COPD Screening event during the same weekend. Respiratory therapists and other medical professionals will be on-site at a display in the manufacturer’s midway at Auto Club Famoso Speedway to provide FREE COPD Screenings and spirometry exams, designed to measure lung function and guide patients towards receiving a COPD diagnosis from their primary care physician or to know their lungs are in great shape.

The Right2Breathe™ Project was co-founded in July 2014 by Joe Morrison and Tim Charlet; two second-generation Drag Racers who have personal experience as caregivers for family members with pulmonary disease including COPD. The Right2Breathe™ Project is targeted to a passionate fan-base of over 50 million individuals in the United States; who share a common passion for motorsports and automotive industry as the organizational co-founders that due to their vocation or lifestyle choices are at high-risk for developing respiratory medical conditions.

“COPD rings home for me and is the core inspiration for Right2Breathe™,” stated Joe Morrison, CEO of Right2Breathe™. “My father was a plumber for several years who raised me in the sport of NHRA Drag Racing. Together we’ve had an active role in New Jersey supporting COPD education, screening and awareness for the past four years. Although he recently passed away due to complications from COPD, my dad’s inspiration strengthens our resolve. With this year’s NHRA CHRR COPD Screening event, we are expanding our reach to our target demographic. Thanks to the support of Novartis® and Sunovion® and the fellow network partners we hope to educate the extensive motorsports fan base about the dangers of COPD and provide them with tools and resources to reduce their risk potential.”

To learn more about the Right2Breathe™ Project, please visit their website at https://www.right2breathe.org. You can also follow them via social media locations on Facebook at http://www.facebook.com/right2breathe and on Twitter @Right_2_Breathe.

Right2Breathe Project Featured at Drive DeVilbiss Night at the Races

A few weeks ago, the Drive DeVilbiss Healthcare Somerset Pennsylvania Family partnered with Right2Breathe.org at the Jennerstown Speedway to raise awareness for COPD. Take a look at this cool video recap they created, that gives just a taste of what the Right2Breathe project is all about. Our thanks to our partners at Drive Devilbiss Healthcare for inviting us to their event! It was a great time!

 

/ In News / By admin / Comments Off on Right2Breathe Project Featured at Drive DeVilbiss Night at the Races

COPD Patients and Caregiver Focus Group at Pulmonary Horizons NYC Conference

PatientCaregiver

As of Saturday July 16th, only 44 spots remain. This event is FREE for COPD Patients and Caregivers in the NYC area. SIGN UP TODAY!

PulmonaryHorizons®

3rd Annual COPD Conference – August 12-14, 2016

PATIENT AND CAREGIVER FOCUS GROUP

HILTON MEADOWLANDS

East Rutherford, NJ

FRIDAY AUGUST 12, 2016 – 10:00 AM TO 2:00 PM

The Most Comprehensive – Integrated Conference – Involving All Stakeholders including the Patient with COPD to Improve Health Outcomes & Reduce Costs

Join Us for the Patient and Caregiver Focus Group! Let Us Know Your Opinion About The Care and Treatment of Patients with COPD

The Focus Group is for Patients with COPD and Caregivers Only

Lunch and Refreshments Provided – Complimentary Registration for the Entire Conference for Patients with COPD and Caregivers

(SPACE IS LIMITED)

Patient and Caregiver Registration Required Click Here

PATIENT AND CAREGIVER FOCUS GROUP

Overview

PURPOSE

The purpose of the focus group is to gather information to help understand the perspectives of patients with COPD, Caregivers and Advocates. Focus groups are helpful for explaining and expanding the results of survey data. They also are helpful to compile information to gain a better understanding and insight into the feelings and desires of patients with COPD.

HOW WILL THE INFORMATION BE USED

The information gained from the focus group will be summarized and used to help support the Roundtable Discussion on Patient and Caregiver Perspectives of The Care and Treatment of Patients with COPD. Patients with COPD and Caregivers are encouraged to attend the conference.  Registration is required.

For More Information Email: coordinator@pulmonaryhorizons.org or Contact:

Alicia Simpson Giles, RRT, MBA, PhD at (602) 819-2181

Michele DaSilva, BA, RRT-NPS at (973) 229-4539

 

 

Volunteers Needed for Pulmonary Horizons Conference in NYC Aug 12 – 14

PulmonaryHorizons®

3rd Annual COPD Conference – August 12-14, 2016

Hilton Meadowlands and MetLife Stadium

East Rutherford, NJ

The Most Comprehensive – Integrated Conference – Involving All Stakeholders including the Patient with COPD to Improve Health Outcomes & Reduce Costs

Volunteer Opportunities for Respiratory Therapists, Registered Nurses, Allied Health and Health Administration Professionals and Students – Receive Complimentary Full Registration, Meals and All Access Throughout the Conference

 

Volunteer Registration Required Click Here

 

CONFERENCE VOLUNTEERS

(Once Registered We Will Contact You with Instructions and Confirm Your Role as a Volunteer)

Volunteer Roles and Responsibilities

Registration Volunteer
Registration volunteers are responsible for welcoming attendees and distributing registration materials. Attendees will expect you to have the answer to everything, so familiarize yourself with the conference schedules, the Conference Onsite Guide, the conference mobile app, room locations, etc.

Volunteer Check-In/Supply Room
Volunteer Check-In/Supply Room volunteers are responsible for checking out supplies to presenters and/or checking in volunteers as they report for duty. This assignment is best done by an administrative assistant who can stay on duty at this post for consecutive days.

Hospitality Table Volunteer
Hospitality volunteers need to be very familiar with the conference schedule; special events, restaurants, and other items that you believe will contribute to an overall positive conference experience including information about the conference for first-time attendees.

Exhibit Hall Volunteer
Exhibit and Sponsor volunteers are responsible for checking in and assisting exhibitors and encouraging participants to visit the exhibits and sponsor presentations.

Traffic Direction Volunteer
Traffic Direction volunteers are responsible for giving directions to conference attendees at posts throughout the conference facility. Attendees will expect you to have the answer to everything, so familiarize yourself with the conference schedules, the Conference Onsite Guide, the conference mobile app, room locations, etc.

Social Media Volunteer
These volunteers must be experienced “Tweeters” who are knowledgeable about tweeting protocol and Twitter best practices (use of hash tags, re-tweeting and attribution, etc.). Volunteers must be on site for the duration of the conference. Volunteers will not be tweeting as official representatives of Pulmonary Horizons but will coordinate with executive staff to ensure consistency of message.

Table Facilitator Volunteer
Table Facilitators will be responsible for leading discussions at their tables during general sessions. During each general session, someone on stage or the announcer will explain what the discussion topics will be and give directions for leading the discussions. Table Facilitators should be outgoing people who are comfortable leading and facilitating conversations.

Drive DeVilbiss Healthcare Sponsors Night at the Races

SOMERSET, PA – June 27, 2016 – Drive DeVilbiss Healthcare will sponsor Saturday Night Thunder racing at the Jennerstown Speedway Complex on July 2.

Fast cars, fun giveaways and exciting races will be the highlight of the event as Drive DeVilbiss Healthcare honors the employees from the Somerset, PA location.

“We’re excited to provide a night of family fun to our employees and the community while raising awareness of Chronic Obstructive Pulmonary Disease, a progressive lung disease that affects millions of Americans,” said Stephanie Murray, Marketing Communications Manager for Drive DeVilbiss Healthcare. “We have partnered with Right2Breathe to provide free, onsite COPD screenings and educational information to anyone who is interested.”

In addition, professional NHRA drag racer and Right2Breathe CEO Joe Morrison will display his Right2Breathe drag car and be available to sign autographs.

“Drive DeVilbiss Healthcare and Right2Breathe share the same commitment to helping people live their lives despite any physical challenges they face. I am excited and honored that Right2Breathe will be a part of the Drive DeVilbiss Healthcare Night at the Races,” Morrison said. “Jennerstown Speedway is a historic track, and we’re looking forward to meeting the fans that come to the fastest paved track in western Pennsylvania.”

Gates open at 4 p.m., and COPD screenings will be available at that time. Racing starts at 6 p.m.

Drive DeVilbiss Healthcare’s main respiratory and sleep device manufacturing facility is located in Somerset and employs 250 local workers.

About Drive DeVilbiss Healthcare

Drive_DeVilbiss-LOGO_rg#D2A

Drive DeVilbiss Healthcare manufactures a complete line of durable medical equipment including mobility products, beds, bariatric products, wheelchairs, sleep surfaces and pressure prevention products, respiratory equipment, self-assist products, power operated wheelchairs, rehabilitation products, patient room equipment, personal care products, electrotherapy devices, respiratory devices and sleep equipment. Currently, the Company has corporate offices and distribution facilities in the United States, Canada, the United Kingdom, Germany, Romania, China and Taiwan. The Company markets its products to customers located throughout the United States, Europe, Canada, Mexico, South America, Latin America, the Middle East and Asia. Drive DeVilbiss is one of the fastest growing major manufacturers and distributors of durable medical equipment.

To learn more go to www.drivemedical.com.

About Right2Breathe

The Right2Breathe™ Inc. is a 501-C non-profit organization based in New Jersey, created by two passionate Drag Racers who have a personal mission to improve the quality of life for those that live with respiratory difficulty, illness or disease. We are dedicated to educating the automotive and motorsports community about pulmonary or respiratory medical conditions through a cause marketing campaign including Chronic Obstructive Pulmonary Disease (COPD), Asthma, Cystic Fibrosis, Influenza, Lung Cancer and Mesothelioma.

The Right2Breathe™ Campaign was co-founded by Joe Morrison and Tim Charlet; two second-generation Drag Racers who have personal experience as caregivers for family members with pulmonary disease. Morrison and Charlet actively support the COPD Patient and Caregiver community and have battled to enact change in legislation at the US Federal and State levels.

Learn more at Right2Breathe.org

About Jennerstown Speedway Complex

Jennerstown Speedway Complex, located in the Laurel Mountains of Western Pennsylvania, is a .522 mile Polymer based asphalt oval with a 550 ft front stretch banked at 6º and turns 700 ft banked at 9º. Weekly Division races include Late Models, Modifieds, Street Stocks, chargers and the Fast and Furious 4s. Special events include IMSA Supermodifieds, Supercup stock car series and Enduro races. The Jennerstown Speedway Complex takes great pride is providing, fun, affordable, family entertainment.  Visit www.Jennerstown.org for more information.

##

Key Contact:

Stephanie K. Murray
Marketing Communications Manager
Email: smurray@drivemedical.com
Tel: (814) 443-7658
Fax: (814) 443-7597

‘Burn Outs’ Documentary About Right2Breathe’s Joe Morrison Featured Nationwide

New Jersey Drag Racer’s story of his pursuit to race professionally in order to raise awareness for father’s COPD diagnosis showcased in ‘Burn Outs’ Documentary Created by ThinkBreatheLive.

BurnoutsBanner1New York, NY. – When crisis arrives, how people handle the situation often defines their legacy. Flemington, NJ resident and North East Timing Association Drag Racing Champion Joe Morrison was placed into this position when his father Chuck Morrison was diagnosed with Chronic Obstructive Pulmonary Disease in 2006. It was at this time that Joe’s mission to become a professional drag racer received an additional nudge and inspired New York’s award winning film production team ThinkBreatheLive to create a documentary called ‘Burn Outs’ – A Dream of Drag Racing that is capturing awards, critical acclaim and most importantly – proving that even the worst situations can produce life changing results.

Based in New York City, TBL began as Breathe Editing in the fall of 2001 with a small office space on 29th street. Working with clients ranging from Jeep® to AT&T, Bayer, Verizon, Nabisco, Coca Cola, and International recording artist Beyoncé, TBL has established a reputation for crafting stimulating visual productions for some of the most successful brands across the globe. During the production of The Right2Breathe Project™, a short film to introduce the non-profit organization Morrison co-founded to raise awareness for his father’s medical condition COPD, TBL’s Kenny Pedini and Director Peter Blackmann were inspired by Morrison’s story and came up with the inspiration for Burn Outs.

“Peter and I met Joe early last summer at Raceway Park in Englishtown, NJ to discuss producing a video for Right2Breathe,” noted Kenny Pedini, the Managing Director of TBL. “While speaking to Joe that day at the racetrack, we could see the passion and enthusiasm that Joe has for the sport.  While interviewing Joe for the Right2Breathe video, we realized that as important as racing is to him, his family is still number one in his life.  That included his ailing dad Chuck, who Joe made it his priority to take care of.  In fact while we were shooting interviews with Joe and Chuck, Joe’s teenage son Ryan was tending to Chuck’s needs – and doing it willingly and happily.  That’s a strong family bond. “

Pedini met Morrison during the production of The Right2Breathe™ Project, a short film starring both Joe and Chuck Morrison along with National, Regional and Local medical news contributor Dr. Nina Radcliff and Vernon Pertelle, the founder of Pulmonary Horizons® to  discuss the mission of Right2Breathe™ and provide justification as to why their National COPD Awareness and Screening program, targeted to the automotive industry will help to solve a medical crisis that impacts the lives of over 24 million people in the United States alone.

“BURN OUTS: A Dream of Drag Racing.” MOVIE TRAILER from ThinkBreatheLive on Vimeo.

“As editor Michael Schwartz and I were finishing up the video, we noticed how Joe’s earnestness came across really strongly in the piece,” Pedini stated. “The idea for Burn Outs was to capture a day in the life of this family guy who just wants to achieve his dream of being a pro racer, and is doing most of it himself.  Three minutes of talking to Joe and then watching him drive will convince you that if anyone can make it, it’s him.”

The documentary Burn Outs has been featured in several film festivals so far, earning the Houston World Fest Gold Remi Award in the process. The film will be showcased at upcoming film festivals across the United States including The Hoboken International Film Festival which takes place June 3 – 9 in Middletown, NY – which coincides with the NHRA’s Summernationals that will be contested June 9th through the 12th at Raceway Park in Englishtown, New Jersey.

“Joe and I are incredibly humbled by the effort ThinkBreatheLive, Kenny Pedini, Peter Blackman and Michael Schwartz have put into Burn Outs and The Right2Breathe Project,” stated Tim Charlet, the Chief Marketing Officer for Right2Breathe™ – a 501 (c)(3) non-profit organization based in New Jersey. “Like Kenny, I was inspired by Joe’s earnestness and honesty when we started working together in 2009. Although his father Chuck recently passed away, his legacy will live forever thanks largely in part to TBL and their production of this exceptional documentary.”

/ In News / By admin / Comments Off on ‘Burn Outs’ Documentary About Right2Breathe’s Joe Morrison Featured Nationwide

BEVESPI AEROSPHERE™ Approved by the US FDA for Patients With COPD

Demonstrated Superior Improvement in Lung Function Versus Mono-Components and Placebo

Only Long Acting Dual Bronchodilator Delivered Through a Pressurized Metered-Dose Inhaler (pMDI) and First Product to Use AstraZeneca’s Patented Co-Suspension™ Technology

WILMINGTON, DE –  AstraZeneca today announced that the US Food and Drug Administration has approved BEVESPI AEROSPHERE (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. BEVESPI AEROSPHERE is not indicated to treat asthma or for the relief of acute bronchospasm.

Sean Bohen, Executive Vice-President, Global Medicines Development and Chief Medical Officer, said: “With the approval of BEVESPI AEROSPHERE we are pleased to provide patients with the first LAMA/LABA in a pressurized metered-dose inhaler, delivered using our unique formulation technology. LAMA/LABAs are emerging as a preferred treatment option for many COPD patients. This class aims to provide maximum bronchodilation, enabling patients to breathe better and may help them be more active.”

BEVESPI AEROSPHERE (glycopyrrolate/formoterol fumarate 9 mcg/4.8 mcg) is a twice-daily, fixed-dose dual bronchodilator combining glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta-2 agonist (LABA). The FDA approval is based on the PINNACLE trial program, which demonstrated that BEVESPI AEROSPHERE achieved statistically significant improvement in morning pre-dose forced expiratory volume in 1 second (FEV1) at 24 weeks (p < 0.001) versus its mono-components and placebo.

LABAs, such as formoterol fumarate, one of the active ingredients in BEVESPI AEROSPHERE, increase the risk of asthma-related death. The most common adverse reactions with BEVESPI AEROSPHERE were urinary tract infection and cough.

BEVESPI AEROSPHERE is the first product approved using AstraZeneca’s Co-Suspension Technology. This technology enables consistent delivery of one or more different medicines from a single pMDI. The technology is being applied to a range of AstraZeneca respiratory inhaled combination therapies currently in clinical development, such as the fixed-dose triple combination of LAMA/LABA/Inhaled corticosteroid (PT010).

INDICATION
BEVESPI AEROSPHERE is a combination of glycopyrrolate, an anticholinergic, and formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA), indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. BEVESPI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma.

Important Safety Information about BEVESPI AEROSPHERE, including Boxed WARNING

WARNING: Long-acting beta2-adrenergic agonists (LABAs), such as formoterol fumarate, one of the active ingredients in BEVESPI AEROSPHERE, increase the risk of asthma-related death. A placebo-controlled trial with another LABA (salmeterol) showed an increase in asthma-related deaths in subjects receiving salmeterol. This finding with salmeterol is considered a class effect of all LABAs, including formoterol fumarate. The safety and efficacy of BEVESPI AEROSPHERE in patients with asthma have not been established. BEVESPI AEROSPHERE is not indicated for the treatment of asthma.

All LABAs are contraindicated in patients with asthma without use of a long-term asthma control medication. BEVESPI is contraindicated in patients with a hypersensitivity to glycopyrrolate, formoterol fumarate, or to any component of the product.

BEVESPI should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition.

BEVESPI should not be used for the relief of acute symptoms, i.e., as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

BEVESPI should not be used more often or at higher doses than recommended, or with other LABAs, as an overdose may result.

If paradoxical bronchospasm occurs, discontinue BEVESPI immediately and institute alternative therapy.

If immediate hypersensitivity reactions, including angioedema, urticaria, or skin rash, occur, discontinue BEVESPI at once and consider alternative treatment.

BEVESPI can produce a clinically significant cardiovascular effect in some patients, as measured by increases in pulse rate, blood pressure, or symptoms. If such effects occur, BEVESPI may need to be discontinued.

Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines.

Be alert to hypokalemia and hyperglycemia.

Worsening of narrow-angle glaucoma or urinary retention may occur. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder-neck obstruction and instruct patients to contact a physician immediately if symptoms occur.

The most common adverse reactions with BEVESPI (≥2% and more common than placebo) were: cough, 4.0% (2.7%), and urinary tract infection, 2.6% (2.3%).

Use caution if administering adrenergic drugs because the sympathetic effects of formoterol may be potentiated.

Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of formoterol.

Use with caution in patients taking non-potassium-sparing diuretics, as the ECG changes and/or hypokalemia may worsen with concomitant beta2-agonists.

The action of adrenergic agonists on the cardiovascular system may be potentiated by monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval. Therefore BEVESPI should be used with extreme caution in patients being treated with these agents.

Use beta-blockers with caution as they not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in patients with COPD.

Avoid co-administration of BEVESPI with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects.

Please see full Prescribing Information including Boxed WARNING, and Medication Guide.

About COPD
COPD (chronic obstructive pulmonary disease) is a progressive disease associated mainly with tobacco smoking, air pollution or occupational exposure, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness. It affects an estimated 329 million people worldwide and is predicted to be the third leading cause of death by 2030. Improving lung function and managing daily symptoms such as breathlessness are important to the management of COPD.

About Co-Suspension Technology
The Co-Suspension Technology uses porous, low-density phospholipid particles, which are designed to form a uniform suspension inside a pressurized metered-dose inhaler (pMDI) and distribution of drug crystals throughout the lungs for release at their sites of deposition.

In addition, Co-Suspension Technology addresses issues often seen when multiple drugs are combined in a pMDI. This technology provides a stable, homogeneous suspension designed to prevent sedimentation of drug crystals over time and to prevent drug crystals from interacting with one another, thus allowing for consistent dosing of one or more different drugs from a single pMDI.

About the PINNACLE studies
The FDA approval of BEVESPI AEROSPHERE is based on data from the PINNACLE 1, PINNACLE 2, and a safety extension study, PINNACLE 3. Overall the Phase III pivotal program enrolled over 3,700 patients with moderate to very severe COPD.

BEVESPI AEROSPHERE demonstrated statistically significant improvements in lung function as measured by change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at 24 weeks (p < 0.001) versus its individual components (glycopyrrolate 9 mcg and formoterol fumarate 4.8 mcg),and placebo, all dosed as 2 inhalations twice daily.

BEVESPI AEROSPHERE demonstrated a significant improvement versus placebo on secondary endpoints of peak FEV1 within 2 hours post-dose and rescue medication usage. There were no unexpected safety findings with adverse events consistent with previous results from the development program. The most common adverse reactions with BEVESPI AEROSPHERE, (with a ≥ 2% incidence and more common than with placebo) were urinary tract infection (2.6% vs 2.3% with placebo) and cough (4.0% vs 2.7% with placebo).

About Respiratory, Inflammation and Autoimmunity Diseases
Respiratory, Inflammation and Autoimmunity (RIA), one of AstraZeneca’s main therapy areas, has five potential medicines in pivotal trials or under registration. In respiratory disease, our aim is to transform asthma and COPD treatment through: Inhaled combinations at the core of care, precision biologics for the unmet needs of specific patient populations, and scientific advancements in disease modification. We are building on a 40-year heritage in respiratory disease, and our capability in inhalation technology spans both pressurized metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs), as well as our unique porous particle Co-Suspension Technology.

In Inflammation and Autoimmunity, our aim is to develop innovative therapies for the treatment of autoimmune and rheumatoid diseases, with a lead program in systemic lupus erythematosus. Across respiratory, inflammation and autoimmune diseases, our research is focused on four key treatable traits: eosinophilic disease, Th2-driven disease, epithelial-driven pathobiology, and autoimmunity.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas — respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology — as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visitwww.astrazeneca-us.com